#USA #San Diego #Robbins LLP #Telix Pharmaceuticals #TLX Class Action

Robbins LLP Launches Class Action Lawsuit Against Telix Pharmaceuticals

Robbins LLP has formally announced the initiation of a class action lawsuit against Telix Pharmaceuticals Ltd. This action aims to represent all investors who acquired shares of Telix (NASDAQ: TLX) between February 21, 2025, and August 28, 2025. Telix Pharmaceuticals is a biopharmaceutical company dedicated to the development and marketing of radiopharmaceuticals and related medical technologies.

Allegations Against Telix Pharmaceuticals

The class action lawsuit is based on allegations that Telix misled its investors about the progress and quality of its products related to prostate cancer therapeutic candidates, specifically TLX591 and TLX592. The lawsuit, filed by Robbins LLP, claims that throughout the specified period, the company's executives provided inflated statements regarding its supply chain's capabilities and the advancement of its therapeutic candidates.

The situation reached a turning point on July 22, 2025, when Telix disclosed it was under investigation by the SEC concerning disclosures about the development of its prostate cancer products. This shocking revelation left investors blindsided and triggered a downturn in stock prices. Further complicating matters, on August 28, 2025, Telix announced receiving a Complete Response Letter (CRL) from the FDA concerning its ZircaixÒ Biologics License Application (BLA). The CRL highlighted significant deficiencies related to chemistry, manufacturing, and controls. The FDA called for additional data to confirm the comparability of the drug used in clinical trials with the process intended for commercial distribution.

Moreover, Telix admitted that notices of deficiency had been issued to its third-party manufacturing partners, which must be resolved before any future submissions of the BLA. This series of events led to a substantial decline in the value of Telix's American Depository Shares (ADSs), raising further concern among investors.

What Should Investors Do Now?

Investors who purchased Telix securities during the stated class period may be eligible to join the lawsuit. If you wish to assume the role of lead plaintiff in this case, your paperwork needs to be submitted to the court by January 9, 2026. The lead plaintiff acts on behalf of all plaintiff class members, influencing the direction of the litigation.

It's important to note that you do not need to participate in the case to recover any losses incurred by the drop in Telix's stock price. Investors have the option to remain as absent class members and still be eligible for potential recoveries.

Robbins LLP indicates that all legal representation is available on a contingency basis. This means that shareholders will not have to pay any fees or expenses unless a recovery is achieved.

About Robbins LLP

Robbins LLP is a respected law firm renowned for its dedication to protecting shareholder rights since 2002. The firm's attorneys are committed to helping shareholders retrieve losses, advocating for better corporate governance, and holding executives accountable for their actions. Their deep expertise in shareholder litigation is aimed at fostering transparency and integrity in the corporate sector.

To stay informed about the progress of the class action against Telix Pharmaceuticals or to receive alerts regarding corporate misconduct, shareholders are encouraged to sign up for Stock Watch. This initiative is designed to keep investors updated on critical legal developments affecting their investments.

For more information or inquiries, investors can contact Robbins LLP directly at 800-350-6003 or reach out to attorney Aaron Dumas, Jr. via email.

This notice serves as a reminder about the importance of diligence during stock evaluations and the need for investors to be proactive about their rights amidst corporate controversies.